FMP
Oncolytics Biotech Inc.
ONCY
NASDAQ
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
0.831 USD
-0.0564 (-6.79%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Wayne F. Pisano M.B.A.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgar...
CIK
0001129928
ISIN
CA6823108759
CUSIP
682310875
Address
322 11th Avenue SW
Phone
14036707380
Country
CA
Employee
29
IPO Date
Oct 5, 2001
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
ONCY Financial Summary
CIK
0001129928
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
682310875
ISIN
CA6823108759
Country
CA
Price
0.83
Beta
1.51
Volume Avg.
539.72k
Market Cap
64.05M
Shares
-
52-Week
0.71-1.53
DCF
0.35
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-3.32
P/B
-
Website
https://www.oncolyticsbiotech.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ONCY News
It looks like there's no news available.
